Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
April 30, 2020

Gilead’s suspension of Covid-19 trials in China should serve as a bellwether for studies in other countries

By Victoria Smith

This month, Gilead suspended its two Covid-19 trials for the promising antiviral remdesivir for moderate-to-severe patients, citing as the reason that the epidemic of Covid-19 has been so well-controlled in China, no eligible patients can be enrolled at present.

As many other regions beset by Covid-19 have implemented measures to control the outbreak, we must consider that there may not be enough patients with Covid-19 to enrol in studies for interventions. Read more here.

Related Companies

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy